Lead sponsor
China-Japan Friendship Hospital
3 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
3
Trials led
3
Active
542
Total enrollment
2
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1/2
1
Phase 4
1
Not applicable
1
Trials by status
By invitation
1
Recruiting
2
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
GLP-1 Therapy After Bariatric Surgery in Chinese Patients With ObesityBMI ≥30not applicableRecruiting200
Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)BMI 24-32.5Ph 4By invitation142